萬春醫藥 BYSI 深 滬
等待開盤 09-27 09:30:00 美东时间
1.76
+0.080
+4.76%
華盛通- 最 高1.76
- 今 開1.7599
- 成交量 9605股
- 最 低 1.65
- 昨 收 1.68
- 總市值 7098.48万
- 52周最高 3.44
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 0.98
- 委 比 -71.35%
- 總股本 4033.23万
- 歷史最高 48.49
- 量 比 0.14
- 振 幅 6.55%
- 歷史最低 0.542
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SEED Therapeutics Secures $6M in Series A-3 Financing
Beyondspring ( ($BYSI) ) has shared an announcement. On September 22, 2025, SEE...
09-23 19:54
Beyondspring Shareholders Ratify Accounting Firm Appointment
The latest announcement is out from Beyondspring ( ($BYSI) ). BeyondSpring Inc....
09-17 04:36
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
Beyond Air公司扩展其LungFit PH全球分销网络，新增日本、韩国等六国，总计覆盖34国，人口27亿。日本由70年经验的AMCO负责。CEO Steve Lisi表示，此举加强了国际市场影响力，正在等待监管审批并提交招标。LungFit PH利用环境空气生成一氧化氮，无需高压气瓶，提升医院效率并减少环境影响，助力 Breath
08-20 12:00
BeyondSpring GAAP EPS of -$0.10
BeyondSpring press release (NASDAQ:BYSI): Q2 GAAP EPS of -$0.10. Cash and cash equivalents: $9.5 million as of June 30, 2025, compared to $2.9 million as of December 2024 More on BeyondSpring Financ...
08-13 22:10
BeyondSpring Q2 EPS $(0.04) Up From $(0.10) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10) per share from the same period last year.
08-13 20:04
BeyondSpring Drug Triggers Immune Response in Patients Who Failed Prior Cancer Immunotherapy
BeyondSpring Inc. (NASDAQ:BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces
07-07 19:04
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
BeyondSpring Inc.的Plinabulin在与放疗和PD-1抑制剂联合治疗中，在8种肿瘤类型中取得23%客观缓解率和54%疾病控制率。研究揭示GEF-H1免疫基因表达可能是预测性生物标志物，并证实Plinabulin通过GEF-H1信号促进树突状细胞成熟，增强抗肿瘤免疫反应。该研究发表在《Med》杂志上。
07-07 11:00
小坑，2只打新！
关键指标【仅供参考】 1、沪深300股债利差择时模型：6.17%，维持100%偏股基金。（持有资金或新增资金均配置节节高混合/雄霸赛道偏股等组合）。 2、万得全...
06-11 08:15
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BeyondSpring Inc. announced interim phase 2 data from the 303 Study at the 2025 ASCO Annual Meeting. The study evaluated Plinabulin, pembrolizumab, and docetaxel in 47 metastatic NSCLC patients who progressed on PD-1/L1 inhibitors. Key results include a median PFS of 6.8 months, a Disease Control Rate of 77.3%, and a 15-month OS rate of 78%, with the combination well-tolerated. The data suggest Plinabulin's potential to reverse resistance to chec...
06-03 11:00
